Labcorp Holdings Inc. (LH)

Labcorp's stock (LH) has experienced movements impacted by several events. As of January 9, 2026, the closing share price was $251.81. The stock was down 3.89% over the past 30 days but up 8.54% over the past 12 months. The 52-week high for LH was $293.72, reached on October 21, 2025, and the 52-week low was $209.38 on April 21, 2025. Key events impacting the stock include solid earnings reports for Q3 2024, Q1 2025, Q2 2025 and Q3 2025. Strategic partnerships and acquisitions, such as collaborations with Praia Health, Providence, Community Health Systems, and Visby, have also influenced the stock. Analysts have a consensus "Moderate Buy" rating for LH, with an average price target of $299.08.

Based on the available information, there is no explicit mention or detailed analysis of demand seasonality for Labcorp Holdings, Inc.'s products and services.

Labcorp Holdings, Inc. is a global life sciences company providing comprehensive laboratory services to support healthcare decisions. It operates in the Healthcare sector, specifically Diagnostics and Biotechnology. The company is divided into two segments: Diagnostics Laboratories (Dx), which offers a range of clinical laboratory tests, and Biopharma Laboratory Services (BLS), which provides drug development and companion diagnostics solutions. Labcorp performs over 700 million tests annually and supported more than 75% of new drugs and therapeutic products approved by the FDA in 2024.

Labcorp has a significant global presence, employing nearly 70,000 people and serving clients in approximately 100 countries. In the U.S., it operates over 2,200 patient service centers. Globally, Labcorp has over 30 U.S. reference and specialty labs for diagnostic testing, and more than 75 global labs focused on research, development, and clinical trial testing. The company is headquartered in Burlington, North Carolina.

Labcorp's brand reputation appears generally positive, driven by expanding diagnostic capabilities and strategic collaborations. The company has expanded its MRD testing for cancer recurrence risk and partnered with Quest to broaden consumer access to at-home PCR tests for STIs. Strategic acquisitions and partnerships, such as with Community Health Systems, Praia Health, and Providence, indicate a proactive approach to strengthening its market position and service delivery. Potential risks, such as adverse shifts in reimbursement policies and challenges related to integrating acquisitions, could indirectly affect public perception if not managed effectively.

Labcorp Holdings Inc. has a diverse ownership structure, with approximately 75.79% of the company's stock owned by institutional investors, 0.30% by insiders, and 23.90% by public companies and individual investors. Other sources indicate institutional ownership at 92.85%, insider ownership at 1.52%, and retail investors at 5.63%. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., and State Street Corp. Vanguard Group Inc. is the largest individual Labcorp Holdings shareholder.